Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14077075 | 0.86 | HSD11B1 (0.36) | HSD11B1HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL19612435 | 0.76 | HSD11B1 (0.38) | HSD11B1CCR1RAB9ACCR5KMT2A | |
| SCHEMBL2285841 | 0.74 | DRD3 (0.42) | RAB9AKMT2A | |
| SCHEMBL4875426 | 0.74 | DRD3 (0.43) | — | |
| SCHEMBL1544072 | 0.69 | HSD11B1 (0.55) | HSD11B1 | |
| SCHEMBL14077078 | 0.69 | HSD11B1 (0.41) | HSD11B1HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL17712835 | 0.66 | HSD11B1 (0.39) | HSD11B1 | |
| SCHEMBL3961491 | 0.65 | CCR1 (0.41) | CCR1RAB9ACCR5OPRK1KMT2A | |
| SCHEMBL31556365 | 0.65 | CCR1 (0.41) | HTR1AHTR1DHTR1BSLC6A4CCR1 | |
| SCHEMBL2883600 | 0.65 | KMT2A (0.56) | CCR1RAB9ACCR5OPRK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003638-B2 | 7-pyrazolylbenzazepines having affinity for D3 receptor | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003638-B2 | 7-pyrazolylbenzazepines having affinity for D3 receptor | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20080312213-A1 | 7-Pyrazolylbenzazepines Having Affinity For D3 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312213-A1 | 7-Pyrazolylbenzazepines Having Affinity For D3 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312213-A1 | 7-Pyrazolylbenzazepines Having Affinity For D3 Receptor | DRD3, HTR3C, GRIN3A | HSD11B1 402/4885HTR1A 319/4885HTR1D 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.